Markets:

Overview

News

Currencies

International

Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

12.90 -0.19 (-1.45%)

Streaming Delayed Price Updated: 10:35 AM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

India Based Pharma Companies In Race To Buy Athenex, Shares Surge ↗

August 05, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

August 05, 2022

Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!

Via InvestorPlace

Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.

July 29, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Eton Pharma Shares Tick Higher After Offloading Hospital Products ↗

June 24, 2022

Via Benzinga

Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

July 27, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

July 22, 2022

From Dr. Reddy’s Laboratories Ltd. 500124

Via Business Wire

Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market

July 08, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx

July 05, 2022

From Aurigene Discovery Technologies Limited

Via Business Wire

Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma

June 24, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market

June 14, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market

May 27, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients ↗

May 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

May 24, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

European Cannabis Q1 2022 Quarterly Update ↗

April 28, 2022

Just like the United States’ state-by-state movement, Europe is moving country-by-country toward providing access to cannabis.

Via Talk Markets

Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market

April 20, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market

April 05, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

Dr. Reddy's Laboratories & MediCane Health To Launch Medical Cannabis Products In Germany ↗

April 01, 2022

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and MediCane Health Inc. announced the launch of its medical cannabis product in Germany.

Via Benzinga

Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany

April 01, 2022

From MediCane Health Inc.

Via Business Wire

Flood Helping Ukraine ↗

March 24, 2022

Emerging markets are gaining as mature markets look risky.

Via Talk Markets

Up On Bad News ↗

March 22, 2022

Despite the plane crash in China, Boeing's stock is up today.

Via Talk Markets

The Ruble Is Rubble ↗

March 03, 2022

MSCI says Russian companies are

Via Talk Markets

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 01, 2022

During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the...

Via Benzinga

Putin on the brink ↗

February 28, 2022

For the first time in history, Swiss banks have penalized account owners for political actions and joined a SWIFT boycott.

Via Talk Markets

Red Ink ↗

February 24, 2022

There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph

Via Talk Markets

Give peace a chance ↗

February 15, 2022

Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today.

Via Talk Markets

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market

February 09, 2022

From Dr. Reddy’s Laboratories Ltd.

Via Business Wire

NYSE-Listed Pharma Co. Dr. Reddy's To Acquire German Medical Cannabis Firm Nimbus Health GmbH ↗

February 04, 2022

Pharmaceutical company Dr. Reddy's Laboratories Ltd. (NYSE:RDY) has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from...

Via Benzinga

Weakened Tech Stocks ↗

February 03, 2022

There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.